Lista de obras -

Australian recommendations for the management of hepatocellular carcinoma: a consensus statement

artículo científico publicado en 2020

Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels

artículo científico publicado en 2019

Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta-analysis

artículo científico publicado en 2020

D-livering the message: The importance of vitamin D status in chronic liver disease ⬇️

artículo científico publicado el 23 de mayo de 2012

Editorial: tailoring mycophenolate mofetil rescue therapy for success in autoimmune hepatitis-authors' reply

artículo científico publicado en 2019

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study

artículo científico publicado en 2017

Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study.

artículo científico publicado en 2017

In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care

scientific article published on 29 August 2020

Increasing prevalence of primary biliary cholangitis in Victoria, Australia

scientific article published on 06 November 2019

Letter: elderly AIH patients-an important subgroup. Authors' reply

scientific article published on 01 September 2019

Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure ⬇️

artículo científico publicado el 12 de enero de 2013

Liver transplantation for cryptogenic cirrhosis ⬇️

artículo científico publicado el 1 de julio de 1997

Nonalcoholic fatty liver disease burden: Australia, 2019-2030

artículo científico publicado en 2020

Reply to: “Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection” ⬇️

artículo científico publicado el 14 de marzo de 2013

Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies ⬇️

artículo científico publicado el 4 de septiembre de 2012

Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.

artículo científico publicado en 2017

Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure ⬇️

artículo científico publicado el 23 de noviembre de 2012

Tranexamic acid without prophylactic factor replacement for prevention of bleeding in hereditary bleeding disorder patients undergoing endoscopy: a pilot study ⬇️

artículo científico publicado el 8 de abril de 2013

Urotensin II Levels Are an Important Marker for the Severity of Portal Hypertension in Children ⬇️

artículo científico publicado el 1 de julio de 2011

Lista de obras de

Australian recommendations for the management of hepatocellular carcinoma: a consensus statement

Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels

Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta-analysis

D-livering the message: The importance of vitamin D status in chronic liver disease ⬇️

Editorial: tailoring mycophenolate mofetil rescue therapy for success in autoimmune hepatitis-authors' reply

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study

Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study.

In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care

Increasing prevalence of primary biliary cholangitis in Victoria, Australia

Letter: elderly AIH patients-an important subgroup. Authors' reply

Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure ⬇️

Liver transplantation for cryptogenic cirrhosis ⬇️

Nonalcoholic fatty liver disease burden: Australia, 2019-2030

Reply to: “Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection” ⬇️

Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies ⬇️

Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.

Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure ⬇️

Tranexamic acid without prophylactic factor replacement for prevention of bleeding in hereditary bleeding disorder patients undergoing endoscopy: a pilot study ⬇️

Urotensin II Levels Are an Important Marker for the Severity of Portal Hypertension in Children ⬇️